Table 2.
Estimated Prevalence* of Chlamydial, Gonococcal, and Antimicrobial Resistant Gonococcal Infections in Persons Aged 15–39 years, by Sex and Age Group, United States, 2018.
| Median Number of Prevalent Infections† (25th–75th percentile) § |
Median Number of Prevalent Infections, per 100,000 Population‡ (25th–75th percentile) § |
|||||
|---|---|---|---|---|---|---|
|
|
||||||
| Men | Women | Total** | Men | Women | Total** | |
|
| ||||||
| Chlamydia || | ||||||
| 15–24 | 595,000 (530,000–659,000) | 990,000 (899,000–1,084,000) | 1,583,000 (1,472,000–1,696,000) | 2,695 (2,401–2,985) | 4,709 (4,276–5,156) | 3,673 (3,415–3,935) |
| 25–39 | 455,000 (371,000–540,000) | 315,000 (250,000–382,000) | 769,000 (662,000–882,000) | 1,348 (1,099–1,600) | 950 (754–1,152) | 1,149 (989–1,318) |
| 15–39** | 1,050,000 (944,000–1,157,000) | 1,306,000 (1,193,000–1,418,000) | 2,353,000 (2,202,000–2,508,000) | 1,881 (1,691–2,072) | 2,410 (2,201–2,616) | 2,138 (2,001–2,279) |
| Gonorrhea ¶ | ||||||
| 15–24 | 20,000 (15,000–27,000) | 90,000 (72,000–115,000) | 113,000 (93,000–138,000) | 91 (68–122) | 428 (342–547) | 262 (216–320) |
| 25–39 | 28,000 (21,000–38,000) | 60,000 (48,000–76,000) | 91,000 (76,000–111,000) | 83 (62–113) | 181 (145–229) | 136 (114–166) |
| 15–39** | 50,000 (40,000–63,000) | 155,000 (131,000–184,000) | 209,000 (183,000–241,000) | 90 (72–113) | 286 (242–339) | 190 (166–219) |
| Antimicrobial Resistant Gonorrhea # | ||||||
| 15–24 | 10,000 (8,000–14,000) | 46,000 (37,000–59,000) | 58,000 (48,000–71,000) | 45 (36–63) | 219 (176–281) | 135 (111–165) |
| 25–39 | 14,000 (11,000–19,000) | 31,000 (25,000–39,000) | 47,000 (39,000–57,000) | 41 (33–56) | 93 (75–118) | 70 (58–85) |
| 15–39** | 26,000 (21,000–32,000) | 80,000 (67,000–94,000) | 107,000 (94,000–124,000) | 47 (38–57) | 148 (124–173) | 97 (85–113) |
Prevalence estimates represent point prevalence, assumed to be at equilibrium, reflective of burden on any given day in 2018.
The number of prevalent infections was rounded to the nearest thousand infections. The number of prevalent chlamydial and gonococcal infections was calculated by multiplying the per capita incidence estimates by the American Community Survey full population estimates for 2018.
Per capita prevalence estimates are represented as the number of prevalent infections per 100,000 population for each age-sex specific subpopulation. All numbers are rounded to the nearest full integer.
Uncertainty intervals represent the 25th and 75th percentiles of the empirical frequency distribution of a given estimate.
The point prevalence of chlamydia was estimated using data from the 2015–2018 cycles of the National Health and Nutrition Examination Survey; these estimates were then used to create a probability distribution of chlamydia prevalence, as described in the Data Inputs Supplement.
The point prevalence of gonorrhea was estimated by finding the close form solution of an ordinary differential equation-based model, assuming equilibrium and static incidence. Details are available in the Mathematical Modeling Supplement.
The prevalence of antimicrobial resistant gonorrhea was determined by multiplying the 2018 percentage (51.3%) of isolates from the Gonococcal Isolate Surveillance Project demonstrating resistance to ciprofloxacin, tetracycline, or penicillin, or elevated minimum inhibitory concentrations to azithromycin, ceftriaxone, or cefixime by the median gonococcal incidence estimates for 2018. (1)
Total and 15–39-year-old estimates are not the sum of individual estimates, but rather descriptions of multiple distributions that have been combined.